Indefinite Delivery Contract 75F40118D10035

This indefinite delivery contract was awarded by the Department of Health and Human Services Food and Drug Administration (FDA) to Battelle Memorial Institute, a non-profit organization and manufacturer of goods. The $10 million master IDIQ contract, titled "Tobacco Products Pharmacology Study", is focused on regulatory and scientific efforts related to tobacco products under the FDA's purview. The contract has resulted in several firm fixed-price delivery orders to Battelle, valued at...

The Department of Health and Human Services Food and Drug Administration awarded a single award Indefinite Delivery Indefinite Quantity contract to Labstat International Inc. to provide tobacco laboratory analysis and engineering services. The contract has a potential value of $45 million over five one-year ordering periods. Three firm fixed price delivery orders have been awarded against the contract to date, including for new smoking regimen services generating and quantitating tobacco smoke...

The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse (NIDA) awarded a single-award $21 million indefinite delivery contract to Altasciences Clinical Kansas Inc., a contract research organization, to conduct pharmacokinetic and pharmacodynamic trials for medication development in substance use disorders. Under this contract, NIDA issued a $1,838,615 firm fixed price delivery order to Altasciences to perform Phase 1 cocaine drug interaction...

The U.S. Food and Drug Administration (FDA), a civilian agency, awarded a $60 million single-award Indefinite Delivery Contract to Research Triangle Institute (RTI International), a non-profit research organization, for the evaluation of the FDA's Center for Tobacco Products' (CTP) public health education campaigns and communication programs. This contract, which does not have a set-aside designation, has an ultimate completion date of August 29, 2026. Under this IDC, RTI has been awarded...

The National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) awarded a $6.5 million single-award Indefinite Delivery Contract (IDC) to the Lovelace Biomedical Research Institute, a not-for-profit contract research organization, to assess potential treatments for drug-induced respiratory depression and overdose toxicity. The contract has a period of performance from September 26, 2022 to September 25, 2027. Under this IDC, NIDA has issued several cost-plus-fixed-fee delivery...

The National Institutes of Health National Institute on Drug Abuse (NIDA) awarded an indefinite delivery contract to the nonprofit Research Triangle Institute (RTI) International for the Preparation and Distribution of Research Drug Products. The contract, valued at up to $19,975,000, has a period of performance from September 20, 2019 to September 19, 2024 and does not utilize any set-aside designations. Under this contract, RTI provides a variety of services to NIDA including the...

The National Institute on Drug Abuse (NIDA), a civilian federal agency, awarded a single-award Indefinite Delivery Contract to Research Triangle Institute (RTI International), a non-profit research organization, for the preparation and distribution of research drug products. The $19,975,000 contract has a period of performance from March 20, 2025 to March 19, 2029, with a final completion date of March 19, 2026 for the initial $1,497,865 delivery order. RTI International, an experienced...

The National Institute on Drug Abuse (NIDA), a civilian agency within the U.S. Department of Health and Human Services, awarded a $7 million indefinite delivery contract to Murty Pharmaceuticals, Inc., a small disadvantaged minority-owned business, for the development and manufacture of pharmaceutical products to support NIDA's substance abuse and addiction treatment research programs. Under this contract, Murty Pharmaceuticals performs a range of services including formulation development,...

The National Institutes of Health (NIH), through its National Institute on Drug Abuse (NIDA), has awarded a Basic Ordering Agreement (BOA) contract to Sri International, a nonprofit research and development institute. The purpose of this $9.75 million, single-award IDV contract is to conduct toxicological evaluations of potential medications to support NIDA's drug abuse research program. Under this IDV, NIDA has issued several cost-plus-fixed-fee task orders to Sri International, valued at...

The National Cancer Institute (NCI) awarded a $74,995,000 multiple-award indefinite delivery/indefinite quantity (IDIQ) contract called the PREVENT Preclinical Drug Development Program to support preclinical pharmacology, toxicology, and product development services for cancer therapy candidates. The prime contractor, IIT Research Institute (IITRI), is a non-profit division of the Illinois Institute of Technology that specializes in these preclinical services for federal agencies. Under this...